Melanoma-Associated Antigen-A (MAGE-A3/A6) -Specific Monoclonal Antibody


A T cell receptor (TCR) recognizing melanoma-associated antigen-A (MAGE-A3/A6) is currently used in clinical trials involving adoptive transfer of TCR-transduced T cells for patients with metastatic cancer. To be eligible for this TCR immunotherapy, tumor specimens from patients must show homogeneous expression of MAGE-A3 and/or MAGE-A6. Currently-available antibodies recognize additional members of the MAGE-A family and/or are cross-reactive because they were raised by epitopes shared among the MAGE-A family members.

MAGE-A3 and MAGE-A6 are members of the MAGE-A family of twelve homologous proteins. The MAGE-A proteins are cancer testis antigens (CTA) that are expressed only in tumor cells and non-MHC expressing germ cells of the testis and placenta. MAGE-A3 and MAGE-A6 proteins are expressed in a variety of human cancers including, but not limited to, melanoma, leukemia, multiple myeloma, synovial cell sarcoma, urothelial cancer and cancers of the breast, thyroid, stomach, pancreas, liver (e.g., hepatocellular carcinoma), lung (e.g., non-small cell lung carcinoma), ovaries, , esophagus, kidney, head (e.g., squamous cell carcinoma), neck (e.g., squamous cell carcinoma), and prostate. 

Researchers at the National Cancer Institute (NCI)  developed a monoclonal antibody against MAGE-A3/A6, where the antibody and antigen binding fragment specifically bind to human MAGE-A3 and human MAGE-A6, and the antibody is a rabbit antibody. The antibody can be used for screening patients eligible for T cell receptor immunotherapy.

The NCI seeks licensing and/or co-development research collaborations to commercialize and develop this monoclonal antibody against MAGE-A3/A6.



Potential Commercial Applications: Competitive Advantages:
  • Diagnostic for patient eligibility screening in immunotherapy
  • May become a diagnostic tool for patients with certain types of cancer
 
  • The NCI invention allows for targeted identification of MAGE-A3 and MAGE-A6, whereas current commercially available MAGE-A3 antibodies are cross-reactive to other members of the MAGE-A family


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-266-2011
E-230-2012


Inventors:

Steven Rosenberg (NCI)  ➽ more inventions...

Yong-Chen Lu (NCI)  ➽ more inventions...

Zhili Zheng (NCI)  ➽ more inventions...

Lucas McDuffie (NCI)  ➽ more inventions...


Intellectual Property:
Application No. 62/425,231
Application No. PCT/US2017/060097

Publications:
Rosenberg SA, et al. Treatment of Patients with Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.  PMID 28809608
Rosenberg SA, et al. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.  PMID 27163739

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-025-2017
Updated: Dec 14, 2018